Diabetes
Conditions
Brief summary
This is a single-center, randomized, open, six-sequence, three-period crossover phase I clinical trial in healthy subjects to compare the PK/PD and safety profiles of single dose of HR20014, INS068, and INS062. In this study, 12 subjects were randomly assigned to 6 administration sequences in a ratio of 1:1:1:1:1:1, and HR20014, INS068 or INS062 injection were given subcutaneously three times before and after each sequence.
Interventions
DRUGINS062 injection、INS068 injection、HR20014 injection
INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects. INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects. HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects.
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The study was a single-center, randomized, open, six-sequence, three-cycle crossover phase I study in healthy subjects. The objective of this trial was to compare the PK/PD and safety of HR20014, INS068 and INS062 in a single subcutaneous injection of the same dose.
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Able and willing to provide a written informed consent; 2. Male or female aged 18-45 at screening (both inclusive); 3. Subjects who are considered to be generally healthy, based on an assessment of medical history, physical examination and clinical laboratory data, as judged by the Investigator; 4. Male weight ≥ 50.0 kg, female weight ≥ 45.0 kg, body mass index (BMI) in 18.0\ 26.0 kg/m2 (both inclusive); 5. During the screening phase oral glucose tolerance test (OGTT), intravenous fasting plasma glucose ≥3.9 mmol/L and \< 6.1 mmol/L; Glucose 2 hours after negative charge static pulse blood sugar \<7.8mmol/L； and normal or abnormal insulin levels have no clinical significance.
Exclusion criteria
1. A history of recurrent or severe drug food allergy, or known or suspected allergy to any component of the study drug; 2. Have a history of hypertension; 3. Severe systemic infectious diseases within 1 month before screening; 4. Patients with a history of lower extremity deep vein thrombosis or high risk of lower extremity deep vein thrombosis; 5. Patients with serious diseases of the psychiatric, cardiovascular, respiratory, digestive, endocrine, blood, urogenital and other systems in the past, or existing diseases of the above systems, were judged by the researchers to be unfit to participate in this study; 6. Use of prescription drugs (topical eye/nasal drops and creams and occasional antipyretic and analgesic drugs such as acetaminophen within recommended doses are permitted) and over-the-counter drugs, and Chinese herbal medicine (regular vitamins are allowed) within 2 weeks before screening; 7. Presence of any abnormal and clinically significant laboratory tests. 8. ECG (12-lead electrocardiogram) showed abnormal and clinically significant. 9. Those who have participated in any drug clinical trials within 3 months or 5 half-life periods before screening (the elder shall prevail), who participated in clinical trials are defined as random, prior to screening. 10. Blood donation within 1 month before screening; Or patients with trauma or major surgical procedures who donated blood or lost blood ≥400 mL in the 3 months prior to screening. 11. Women who are pregnant, breastfeeding or planning to conceive, or women of childbearing potential (WOCBP) are reluctant to use appropriate contraception during the trial. 12. The investigators determined that other conditions were inappropriate for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the Glucose Infusion Rate (GIR) - time curve (Only for HR20014 and INS068） | 0 hour to 6 hours after dosing |
| Area under the Glucose Infusion Rate (GIR) - time curve (Only for HR20014 and INS062） | 6 hours to 24 hours after dosing |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the Glucose Infusion Rate (GIR) - time curve | 0 hour to 96 hours after dosing | Based on the absolute dose and concentration of INS068 |
| Maximum concentration of INS068 | 0 hour to 96 hours after dosing | Based on the absolute dose and concentration of INS068 |
| Maximum concentration of INS062 | 0 hour to 10 hours after dosing | Based on the absolute dose and concentration of INS062 |
| Incidence and severity of adverse events (AEs) | from screening to 7-21 days after the last dosing | — |
Countries
China
Outcome results
None listed